Target
RAF
Aliases
Raf
12 products, 19 indications
Indications
hepatocellular carcinoma (4 products)
KRAS G12C-mutated solid tumors (3 products)
Metastatic colorectal cancer (2 products)
advanced hepatocellular carcinoma (2 products)
Advanced melanoma (2 products)
recurrent low-grade serous ovarian cancer (2 products)
glioblastoma (1 products)
Recurrent Glioblastoma, Non-Small Cell Lung Cancer (1 products)
KIT-mutated melanoma (1 products)
GIST (1 products)
metastatic non-small cell lung cancer (1 products)
Stage III melanoma (1 products)
melanoma brain metastases (1 products)
Metastatic Cancer (1 products)
Unresectable hepatocellular carcinoma (1 products)
BRAF class II mutant/fusion positive/intragenic deletion solid tumours (1 products)
BRAF class III mutant solid tumours (1 products)
RAS or RAF mutated solid tumors (1 products)
NRAS-mutant unresectable stage III or IV melanoma (1 products)
Loading...
5 drugs
3 abstracts
Abstract
Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Investigational Cancer Therapeutics,
Abstract
Phase IB study of tovorafenib for children with relapsed/recurrent low-grade gliomas and other MAPK pathway activated tumors.Org: Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Children's Hospital of Philidelphia, St. Louis Children's Hospital, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, Massachusetts General Hospital,
Abstract
A first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors.Org: Oncology Virginia,
Drug
RegorafenibDrug
sorafenibDrug
belvarafenibDrug
avutometinibDrug
donafenib